Human iPS to neuron (wt) 2: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
(8 intermediate revisions by 3 users not shown) | |||
Line 7: | Line 7: | ||
|series=IN_VITRO DIFFERENTIATION SERIES | |series=IN_VITRO DIFFERENTIATION SERIES | ||
|species=Human (Homo sapiens) | |species=Human (Homo sapiens) | ||
|zenbu_config= | |zenbu_config=https://fantom.gsc.riken.jp/zenbu/gLyphs/#config=vskew4ZLGV1qCO_gqVCI6D | ||
|TCOverview=Human induced pluripotent stem cells can generate every cell type of the human body and under the appropriate conditions recapitulate central aspects of embryonic development in the dish. To interrogate the transcriptome changes associated with the earliest steps of human brain development as recapitulated with human pluripotent stem cells we generated footprint-free induced pluripotent stem cells (iPSC) from control and Down syndrome fibroblasts using episomal reprogramming [1] and were next stepwise differentiated these iPSc into neuro-ectodermal cells (day6), neural stem cells (day12) and early neuronal progenitors (day 18) using an established neuronal differentiation protocol [2].<br> | |TCOverview=Human induced pluripotent stem cells can generate every cell type of the human body and under the appropriate conditions recapitulate central aspects of embryonic development in the dish. To interrogate the transcriptome changes associated with the earliest steps of human brain development as recapitulated with human pluripotent stem cells we generated footprint-free induced pluripotent stem cells (iPSC) from control and Down syndrome fibroblasts using episomal reprogramming [1] and were next stepwise differentiated these iPSc into neuro-ectodermal cells (day6), neural stem cells (day12) and early neuronal progenitors (day 18) using an established neuronal differentiation protocol [2].<br> | ||
<br> | <br> | ||
Line 15: | Line 15: | ||
|TCSample_description=For this study three sample donors were used, two 2 control iPSC (C11 iPSC derived from CRL2429 Newborn Male Caucasian fibroblasts and C32 iPSC derived from CRL1502 12wk gestation Female Black fibroblasts) and two iPSC clones from one Down Syndrome individual (C11 and C18 from an Unknown Male Caucasian). Three replicates of each iPSc line were subjected to neuronal differentiation as described [1,2] and harvested at day 0, 6, 12, 18 of differentiation for RNA extraction (Fig 1 below).<br> | |TCSample_description=For this study three sample donors were used, two 2 control iPSC (C11 iPSC derived from CRL2429 Newborn Male Caucasian fibroblasts and C32 iPSC derived from CRL1502 12wk gestation Female Black fibroblasts) and two iPSC clones from one Down Syndrome individual (C11 and C18 from an Unknown Male Caucasian). Three replicates of each iPSc line were subjected to neuronal differentiation as described [1,2] and harvested at day 0, 6, 12, 18 of differentiation for RNA extraction (Fig 1 below).<br> | ||
<br> | <br> | ||
<html><img src=' | <html><img src='/resource_browser/images/TC_qc/800px-Protocol_copy.jpg' width='700px'></html> | ||
Figure 1: Phase microscope images of neuronally differentiated hIPSC (C32 shown) and a graphical depiction of the timepoints where RNA was harvested for CAGE analysis.<br> | Figure 1: Phase microscope images of neuronally differentiated hIPSC (C32 shown) and a graphical depiction of the timepoints where RNA was harvested for CAGE analysis.<br> | ||
<br> | <br> | ||
Line 23: | Line 23: | ||
|TCQuality_control=Q-PCR validation of key neuronal marker genes was performed and published [1]. The data show upregulation of mRNA expression of the neuronal marker genes PAX6 [3] , beta-III-tubulin [4], SOX1 [5] , DCX [6], SOX9 [7], SOX2 [8] and MASH1 [9] (Fig 2C and D) and robust expression of PAX6, beta-III-Tubulin and MAP2 [10] protein expression (Fig 2A). we further expect that as cells exit from pluripotency that they will display a downregulation of the pluripotency transcription factor Oct4 [11] and the DNA methyl transferase DNMT3B [12].<br> | |TCQuality_control=Q-PCR validation of key neuronal marker genes was performed and published [1]. The data show upregulation of mRNA expression of the neuronal marker genes PAX6 [3] , beta-III-tubulin [4], SOX1 [5] , DCX [6], SOX9 [7], SOX2 [8] and MASH1 [9] (Fig 2C and D) and robust expression of PAX6, beta-III-Tubulin and MAP2 [10] protein expression (Fig 2A). we further expect that as cells exit from pluripotency that they will display a downregulation of the pluripotency transcription factor Oct4 [11] and the DNA methyl transferase DNMT3B [12].<br> | ||
<br> | <br> | ||
<html><img src=' | <html><img src='/resource_browser/images/TC_qc/800px-Human_iPS_differentiation_QC1.png' onclick='javascript:window.open("/resource_browser/images/TC_qc/800px-Human_iPS_differentiation_QC1.png", "imgwindow", "width=800,height=650");' style='width:700px;cursor:pointer'/></html><br> | ||
<br> | <br> | ||
Figure 2: Immunofluorescent detection of neuronal marker proteins beta-III-tubulin, MAP2 and PAX6 in neuronally differentiated hIPSc cultures (A) and Q-PCR mRNA expression quantification of key neuronal genes (B and C) in these samples. Reproduced from [1].<br> | Figure 2: Immunofluorescent detection of neuronal marker proteins beta-III-tubulin, MAP2 and PAX6 in neuronally differentiated hIPSc cultures (A) and Q-PCR mRNA expression quantification of key neuronal genes (B and C) in these samples. Reproduced from [1].<br> | ||
Line 41: | Line 41: | ||
Figure 3 A-D shows the CAGE expression of DNMT3B, MAP2, PAX6, beta-III-tubulin and Oct4 in the two two DS iPSC (A and B) and control iPSC (C and D) subjected to neuronal differentiation. The expected down regulation of the pluripotency markers and upregulation of neuronal identity genes is observed. | Figure 3 A-D shows the CAGE expression of DNMT3B, MAP2, PAX6, beta-III-tubulin and Oct4 in the two two DS iPSC (A and B) and control iPSC (C and D) subjected to neuronal differentiation. The expected down regulation of the pluripotency markers and upregulation of neuronal identity genes is observed. | ||
<br> | <br> | ||
<html><img src=' | <html><img src='/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_down-syndrome-C11.png' onclick='javascript:window.open("/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_down-syndrome-C11.png", "imgwindow", "width=1000,height=375");' style='width:700px;cursor:pointer'/></html><br> | ||
Figure 3A<br> | Figure 3A<br> | ||
<br> | <br> | ||
<html><img src=' | <html><img src='/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_down-syndrome-C18.png' onclick='javascript:window.open("/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_down-syndrome-C18.png", "imgwindow", "width=1000,height=375");' style='width:700px;cursor:pointer'/></html><br> | ||
Figure 3B<br> | Figure 3B<br> | ||
<br> | <br> | ||
<html><img src=' | <html><img src='/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_control-C11.png' onclick='javascript:window.open("/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_control-C11.png", "imgwindow", "width=1000,height=375");' style='width:700px;cursor:pointer'/></html><br> | ||
Figure 3C<br> | Figure 3C<br> | ||
<br> | <br> | ||
<html><img src=' | <html><img src='/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_control-C32.png' onclick='javascript:window.open("/resource_browser/images/TC_qc/Human_iPS_differentiation_to_neuron_control-C32.png", "imgwindow", "width=1000,height=375");' style='width:700px;cursor:pointer'/></html><br> | ||
Figure 3D<br> | Figure 3D<br> | ||
<br> | <br> | ||
Line 69: | Line 69: | ||
[12] Okano, Masaki, Daphne W. Bell, Daniel A. Haber, and En Li. "DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development." Cell 99, no. 3 (1999): 247-257.<br> | [12] Okano, Masaki, Daphne W. Bell, Daniel A. Haber, and En Li. "DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development." Cell 99, no. 3 (1999): 247-257.<br> | ||
<br> | <br> | ||
|germ_layer=ectoderm | |||
|primary_cells=primary cells | |||
|category_treatment=Differentiation | |||
|timepoint_design=Staged in-vitro diff | |||
|time_span=18 days | |||
|number_time_points=4 | |||
|time_points=day00 | |||
|tissue_cell_type=iPS>>neuron | |||
|zenbu_config=https://fantom.gsc.riken.jp/zenbu/gLyphs/#config=Am4hgtVNOtbjWqRFo0eVr | |||
|tet_config=https://fantom.gsc.riken.jp/5/suppl/tet/Human_iPS_differentiation_to_neuron_control_C32.tsv.gz | |||
|tet_file=https://fantom.gsc.riken.jp/5/tet#!/search/?filename=hg19.cage_peak_phase1and2combined_tpm_ann_decoded.osc.txt.gz&file=1&c=1&c=1452&c=1453&c=1454&c=1455&c=1456&c=1457&c=1458&c=1459&c=1460&c=1461&c=1462&c=1463 | |||
}} | }} |
Latest revision as of 17:13, 14 March 2022
Series: | IN_VITRO DIFFERENTIATION SERIES |
---|---|
Species: | Human (Homo sapiens) |
Genomic View: | Zenbu |
Expression table: | FILE |
Link to TET: | TET |
Sample providers : | Christine Wells |
Germ layer: | ectoderm |
Primary cells or cell line: | primary cells |
Time span: | 18 days |
Number of time points: | 4 |
Overview |
---|
Human induced pluripotent stem cells can generate every cell type of the human body and under the appropriate conditions recapitulate central aspects of embryonic development in the dish. To interrogate the transcriptome changes associated with the earliest steps of human brain development as recapitulated with human pluripotent stem cells we generated footprint-free induced pluripotent stem cells (iPSC) from control and Down syndrome fibroblasts using episomal reprogramming [1] and were next stepwise differentiated these iPSc into neuro-ectodermal cells (day6), neural stem cells (day12) and early neuronal progenitors (day 18) using an established neuronal differentiation protocol [2]. |
Sample description |
---|
For this study three sample donors were used, two 2 control iPSC (C11 iPSC derived from CRL2429 Newborn Male Caucasian fibroblasts and C32 iPSC derived from CRL1502 12wk gestation Female Black fibroblasts) and two iPSC clones from one Down Syndrome individual (C11 and C18 from an Unknown Male Caucasian). Three replicates of each iPSc line were subjected to neuronal differentiation as described [1,2] and harvested at day 0, 6, 12, 18 of differentiation for RNA extraction (Fig 1 below). |
Quality control |
---|
Q-PCR validation of key neuronal marker genes was performed and published [1]. The data show upregulation of mRNA expression of the neuronal marker genes PAX6 [3] , beta-III-tubulin [4], SOX1 [5] , DCX [6], SOX9 [7], SOX2 [8] and MASH1 [9] (Fig 2C and D) and robust expression of PAX6, beta-III-Tubulin and MAP2 [10] protein expression (Fig 2A). we further expect that as cells exit from pluripotency that they will display a downregulation of the pluripotency transcription factor Oct4 [11] and the DNA methyl transferase DNMT3B [12]. |
Profiled time course samples
Only samples that passed quality controls (Arner et al. 2015) are shown here. The entire set of samples are downloadable from FANTOM5 human / mouse samples
13433-144E4 | iPS differentiation to neuron, control donor C32-CRL1502 | day00 | rep1 |
13434-144E5 | iPS differentiation to neuron, control donor C32-CRL1502 | day06 | rep1 |
13435-144E6 | iPS differentiation to neuron, control donor C32-CRL1502 | day12 | rep1 |
13436-144E7 | iPS differentiation to neuron, control donor C32-CRL1502 | day18 | rep1 |
13437-144E8 | iPS differentiation to neuron, control donor C32-CRL1502 | day00 | rep2 |
13438-144E9 | iPS differentiation to neuron, control donor C32-CRL1502 | day06 | rep2 |
13439-144F1 | iPS differentiation to neuron, control donor C32-CRL1502 | day12 | rep2 |
13440-144F2 | iPS differentiation to neuron, control donor C32-CRL1502 | day18 | rep2 |
13441-144F3 | iPS differentiation to neuron, control donor C32-CRL1502 | day00 | rep3 |
13442-144F4 | iPS differentiation to neuron, control donor C32-CRL1502 | day06 | rep3 |
13443-144F5 | iPS differentiation to neuron, control donor C32-CRL1502 | day12 | rep3 |
13444-144F6 | iPS differentiation to neuron, control donor C32-CRL1502 | day18 | rep3 |